Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years

• Published in: Transplantation proceedings Vol. 48; no. 1; pp. 177 - 184
• Main Authors: Remenyi, P, Varga, G, Mikala, G, Reti, M, Gopcsa, L, Batai, A, Csukly, Z, Lengyel, L, Torbagyi, E, Barta, A, Fabian, J, Levai, D, Szombath, G, Andrikovics, H, Masszi, T
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2016
• Subjects: Adult; Age Factors; Aged; Antineoplastic Agents - administration & dosage; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic Stem Cell Transplantation - mortality; Humans; Interferons - administration & dosage; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma - therapy; Remission Induction; Retrospective Studies; Surgery; Time-to-Treatment; Transplantation, Autologous - methods; Transplantation, Autologous - mortality
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2015.12.031

Abstract Background Autologous stem cell transplantation (ASCT) has become the mainstay of 1st-line treatment in younger patients with multiple myeloma (MM), but statistical confirmation of its superiority over other therapies, especially in the era of novel agents, is still lacking. Methods We reviewed the results of all 548 myeloma ASCTs performed in our institute over the past 18 years. Results More than one-half of the patients had access to novel agents before their transplantations. Although the age of the transplanted patients increased significantly over the years, treatment-related mortality (TRM) was remarkably low, especially in 1st-line transplanted patients (100-day TRM, 0.3%). The median overall survival (OS) of the entire cohort was 98.4 months. Patients transplanted within 12 months from the start of their therapy had significantly better responses than those having delayed ASCT (complete response rate, 58.1% vs 46.8%; P  = .016) and significant post-ASCT progression-free survival (PFS) benefit (30.2 [26.1–34.3] mo vs 23.3 [16.8–29.8] mo; P  = .036), but we found no significant overall survival difference. The results were similar in patients treated with or without novel agents before ASCT. During a period of time, interferon maintenance was our standard approach to post-ASCT maintenance. Our analysis showed not only a significant PFS advantage with interferon, but also a highly significant overall survival benefit (150.4 [105.1–195.8] mo vs 86.1 [72.5–99.7] mo; P  = .003). Conclusions Our findings demonstrate that delayed ASCT can be feasible in selected patients.